The preset invention relates to a composition for treating lupus erythematosus, particularly lupus nephritis, comprising a therapeutically effective amount of epigallocatechin-3-gallate (EGCG) or a pharmaceutically acceptable salt or a physiologically functional derivative, together with one or more pharmaceutically acceptable carriers, diluents or excipients.